Drug Profile
Research programme: oral therapeutics - Seoul Pharma
Alternative Names: SPO 1107; SPO 1304; SPO 1401; SPO 1405; SPO 1406Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Seoul Pharma
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Nausea and vomiting; Obesity; Overactive bladder; Viral infections
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Hyperlipidaemia in South Korea
- 28 Oct 2019 No recent reports of development identified for research development in Nausea and vomiting in South Korea (PO, Film)
- 28 Oct 2019 No recent reports of development identified for research development in Obesity in South Korea (PO, Film)